Nov 9 (Reuters) - IntelGenx Technologies Corp
* IntelGenx submits Montelukast VersaFilm(tm) clinical trial application with Health Canada
* IntelGenx - submitted CTA to Health Canada for approval to initiate its Phase 2a POC study with Montelukast in mild to moderate alzheimer’s disease Source text for Eikon: Further company coverage: